STRATEC Annual General Meeting approves record dividend and elects new Supervisory Board member

Birkenfeld, June 14, 2017

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard) held its Annual General Meeting today in Pforzheim. The company's shareholders approved all proposals submitted for resolution with clear majorities. Around 77% of the company's share capital was represented at the meeting.

As proposed, STRATEC will be distributing a dividend of EUR 0.77 per share to its shareholders for the successful 2016 financial year (previous year: EUR 0.75 per share). This is already the thirteenth consecutive increase since dividend payments started in 2004. The distribution total amounts to EUR 9.1 million and will be paid out to shareholders via their depositing banks on June 20, 2017.

Furthermore, shareholders approved the actions of the Board of Management and the Supervisory Board and elected Rainer Baule (68), Managing Director of Baule GmbH and former CEO of Fresenius Kabi AG, to the Supervisory Board. He will succeed Wolfgang Wehmeyer, who retired from the Supervisory Board at his own request upon the conclusion of the Annual General Meeting. STRATEC's Board of Management and Supervisory Board would like to take this opportunity to thank Mr. Wehmeyer for the good and close working relationship over the years.

Shareholders also approved all other agenda items with large majorities in each case.

Further information about our Annual General Meeting can be found on the company's website at www.stratec.com/agm, where details of voting results have also been published.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com